| |
|
|
|
|
|
|
| R'000 |
Number of shares
(’000) |
Share
capital
(Note 8) |
Share
premium
(Note 8) |
Non-
distributable
reserve |
Distributable
reserve |
Total |
| Balance at 31 August 2001 |
298 541 |
2 985 |
496 690 |
50 216 |
(8 837) |
541 054 |
| Capitalisation awards |
3 549 |
36 |
25 767 |
– |
– |
25 803 |
| Shares issued in respect of options |
3 082 |
31 |
14 118 |
– |
– |
14 149 |
| Foreign currency translation reserve |
|
– |
– |
74 213 |
– |
74 213 |
| Profit for the year |
|
– |
– |
– |
80 869 |
80 869 |
| Distributions |
|
– |
– |
– |
(63 539) |
(63 539) |
| Balance at 31 August 2002
|
305 172 |
3 052 |
536 575 |
124 429 |
8 493 |
672 549 |
| Capitalisation awards |
6 165 |
62 |
37 300 |
– |
– |
37 362 |
| Shares issued in respect of options |
1 933 |
19 |
9 753 |
– |
– |
9 772 |
| Share issue expenses |
– |
– |
(1 053) |
– |
– |
(1 053) |
| Acquisition of New United Pharmaceutical |
|
|
|
|
|
|
| Distributors |
40 848 |
408 |
293 698 |
– |
– |
294 106 |
| Foreign currency translation reserve |
|
– |
– |
(65) |
– |
(65) |
| Profit for the year |
|
– |
– |
– |
95 098 |
95 098 |
| Distributions |
|
– |
– |
– |
(81 605) |
(81 605) |
| Balance at 31 August
2003 |
354 118 |
3 541 |
876 273 |
124 364 |
21 986 |
1 026 164 |
| The non-distributable reserve comprises
the unrealised gain on the translation of assets and liabilities denominated
in foreign currencies. |
| |
